Federico Grossi, M.D., Ph.D., served as the Chief Medical Officer at Apellis Pharmaceuticals until his departure on January 3, 2023. His career showcases a strong focus on medicine and clinical development, bringing years of leadership experience to the biopharmaceutical field....

Federico Grossi, M.D., Ph.D., served as the Chief Medical Officer at Apellis Pharmaceuticals until his departure on January 3, 2023. His career showcases a strong focus on medicine and clinical development, bringing years of leadership experience to the biopharmaceutical field. He played key roles in multiple clinical trials that pushed innovative treatments forward. Notably, Grossi's annual compensation in 2023 was $1,411,838, largely driven by a performance-based bonus system, emphasizing results over a fixed salary. He transitioned from being the Executive Vice President of Clinical Development, reflecting a career trajectory that highlights his deep involvement in critical drug development processes. Additionally, his academic background, which includes both an M.D. and a Ph.D. in physiology, underscores his comprehensive understanding of medicine and science. Federico's insights into clinical operations and his commitment to advancing medical treatments have left a mark on the industry, particularly at Apellis.